Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2023-08-18 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
2023年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2023 半年度报告摘要' which translates to '2023 Semi-Annual Report Summary'. It contains detailed financial data for the half-year period, including revenue, net profit, earnings per share, and asset information. It also includes shareholder information and notes on important matters during the period. The document is about 2870 characters long, which is relatively short but contains substantive financial data and analysis for a half-year period. This matches the definition of an Interim / Quarterly Report (IR), which requires comprehensive financial data for a period shorter than a full fiscal year. It is not merely an announcement or a summary without data, but actual financial figures and company performance details are included. Therefore, the correct classification is IR with high confidence. H1 2023
2023-08-18 Chinese
金陵药业关于公司申请向特定对象发行股票的审核问询函回复及募集说明书等申请文件更新的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from Jinling Pharmaceutical Co., Ltd. regarding the company's response to a review inquiry letter from the Shenzhen Stock Exchange about its application for a private placement of shares. It mentions updates to the application documents and financial data, references regulatory bodies (Shenzhen Stock Exchange and China Securities Regulatory Commission), and states that the issuance is subject to approval. The document is short (856 characters) and primarily serves as an announcement of updates and regulatory review status rather than containing detailed financial data or the actual issuance report. Therefore, it fits best as a Capital/Financing Update (CAP) since it relates to a financing activity (private placement) and updates on the process.
2023-07-21 Chinese
金陵药业股份有限公司最近一年的财务报告及其审计报告以及最近一期的财务报告
Audit Report / Information Classification · 100% confidence The document is titled '审计报告' which translates to 'Audit Report'. It contains detailed auditor opinions, audit basis, key audit matters such as goodwill impairment and accounts receivable bad debt provisions, and extensive financial statement data including balance sheets and profit statements for the year ending December 31, 2022. The presence of auditor signatures and references to Chinese auditing standards further confirm this is a standalone audit report. The document is about 15,000 characters long and contains substantive financial data and audit analysis, not merely an announcement or certification. Therefore, it fits the category of an Audit Report / Information (AR). FY 2022
2023-07-21 Chinese
中信证券股份有限公司关于金陵药业股份有限公司2023年度向特定对象发行A股股票之发行保荐书（修订稿）
Capital/Financing Update Classification · 95% confidence The document is titled as an "发行保荐书" (Issuance Sponsorship Letter) related to a specific issuance of A shares by Jinling Pharmaceutical Company Limited in 2023. It is issued by CITIC Securities as the sponsor for this specific share issuance. The content includes detailed information about the sponsor, the issuer, shareholding structure, financial data, and regulatory compliance statements. This document is not a general annual report or earnings release but a formal sponsorship letter related to a capital raising event (share issuance). It is a detailed document about the financing activity, not just an announcement or a brief summary. Therefore, it fits the category of Capital/Financing Update (CAP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2023-07-21 Chinese
江苏泰和律师事务所关于金陵药业股份有限公司2023年度向特定对象发行A股股票的补充法律书（二）
Capital/Financing Update Classification · 95% confidence The document is a detailed legal opinion letter from a law firm regarding a company's 2023 private placement of A shares. It includes extensive legal and regulatory compliance checks, responses to inquiry letters from the Shenzhen Stock Exchange, and detailed descriptions of the issuance process, project investments, and legal qualifications. The document is titled as a "Supplementary Legal Opinion Letter (II)" related to a specific stock issuance. It is not a financial report, earnings release, or management discussion, but a legal opinion supporting a capital raising event. This fits the category of Capital/Financing Update (CAP), as it relates to the issuance of shares to specific investors and the legal opinions supporting that issuance. The document length (15,000 characters) and content confirm it is a substantive legal opinion, not a brief announcement or certification, so it is not RNS or RPA. Therefore, the best classification is CAP with high confidence.
2023-07-21 Chinese
天衡会计师事务所(特殊普通合伙)关于金陵药业股份有限公司申请向特定对象发行股票的审核问询函的回复
Interim / Quarterly Report Classification · 95% confidence The document is a detailed response to an inquiry letter regarding a company's application for a specific stock issuance. It contains extensive financial data, including revenue, profit, cost breakdowns, and analysis of business segments over multiple years and quarters. The document includes audit references and detailed financial explanations, indicating it is a comprehensive financial report rather than a brief announcement or certification. The presence of detailed financial statements and management discussion aligns with an Interim / Quarterly Report (IR) classification, as it covers a period shorter than a full fiscal year and provides substantive financial data and analysis. It is not an Annual Report (10-K) because it focuses on recent quarters and specific financial inquiries related to a stock issuance, nor is it an Audit Report (AR) as it is not solely an audit opinion. Therefore, the best fit is Interim / Quarterly Report (IR). Q1 2023
2023-07-21 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.